Drug Search Results
More Filters [+]

grass pollen

Alternative Names: grass pollen
Latest Update: 2024-10-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Oral,Sublingual,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Czech | Denmark | Estonia | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Allergy Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for grass pollen

Countries in Clinic: Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Poland, Romania, Slovakia, Spain, United Kingdom

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Asthma, Allergic|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal

Phase 2: Grass Pollen Hypersensitivity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PQGrass308

P3

Unknown Status

Conjunctivitis, Allergic|Rhinitis, Allergic, Seasonal

2032-10-31

SC-3C2A

P3

Unknown Status

Conjunctivitis, Allergic|Rhinitis, Allergic|Asthma, Allergic

2026-09-30

PM/0059

P3

Unknown Status

Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Conjunctivitis, Allergic

2026-08-31

2023-505880-35-00

P3

Unknown Status

Rhinitis, Allergic|Conjunctivitis, Allergic|Asthma, Allergic

2025-10-30

Recent News Events